Introduction
============

Thyroid carcinoma coexisting with hyperthyroidism is an uncommon occurrence ([@b1-mco-0-0-1927]), as low thyroid-stimulating hormone (TSH) levels can suppress the development and growth of differentiated thyroid carcinoma cells. The majority of nodules in patients with low TSH levels are considered to be benign (NCCN, British Thyroid Association) ([@b1-mco-0-0-1927]); however, an increasing number of thyroid carcinoma cases are diagnosed in patients with Graves\' disease, toxic goiter and functioning thyroid adenoma ([@b2-mco-0-0-1927]). These thyroid carcinomas may be embedded in or adjacent to a larger hot nodule, and the majority are non-functional. However, previous studies have reported that hyperfunctioning thyroid carcinoma may present as autonomous functioning thyroid nodules (AFTN) within the thyroid gland, or as functioning lesions in metastatic foci ([@b3-mco-0-0-1927]--[@b5-mco-0-0-1927]). In addition, Als *et al* ([@b3-mco-0-0-1927]) identified 19 patients with toxic thyroid carcinoma in 2002, while Mirfakhraee *et al* ([@b5-mco-0-0-1927]) identified a solitary hyperfunctioning thyroid nodule harboring thyroid carcinoma and reported 76 cases of malignant hot thyroid nodules based on a literature search. Hyperfunctioning thyroid carcinomas are capable of absorbing iodine, as well as synthesizing and releasing thyroxine. Patients with hyperfunctioning thyroid carcinomas may therefore present with clinical thyrotoxicosis. It is considered that this type of hyperthyroidism may be caused by hyperfunctioning thyroid carcinoma. However, as the incidence of hyperfunctioning thyroid carcinoma is very low, diagnosis may be delayed and the subsequent choice of treatment may be unsuitable. Therefore, the aim of the present study was to improve our understanding of hyperfunctioning thyroid carcinoma in order to prevent misdiagnosis and to identify the most effective treatment strategies.

Materials and methods
=====================

### Search strategy and selection criteria

A literature search of PubMed for studies published in English between January 1990 and July 2017 was performed using the terms, 'hyperfunctioning thyroid carcinoma/cancer', 'malignant hot/toxic thyroid nodule', or 'hyperfunctioning papillary/follicular/Hürthle cell thyroid carcinoma', followed by a review of the identified articles. Hyperfunctioning thyroid carcinoma was divided into primary and metastatic. The inclusion criteria for studies involving primary hyperfunctioning thyroid carcinoma were as follows: i) Thyroid carcinoma, papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) or Hürthle cell carcinoma (HCC); ii) clinical hyperthyroidism with symptomatically or biochemically diagnosed thyrotoxicosis; iii) AFTN, hot or warm nodules (as determined by scintigraphy) and other thyroid tissues with suppressed uptake (^99m^Tc, and/or ^131^I or ^123^I); iv) thyroid carcinomas of an identical size to hot or warm nodules, or the absence of hyperplasia in non-cancerous thyroid tissues on pathological analysis. Studies involving cases where the size of the thyroid carcinoma was not identical to that of the hot or warm nodules on scintigraphy, or those where this information was not included, were excluded from the present study, as these tumors may be embedded in hot benign nodules and be non-functional. The inclusion criteria for studies involving metastatic hyperfunctioning thyroid carcinoma were required to meet aforementioned points i, ii and iii; or i, ii and iv; or a minimum of points i, ii and vi of the following: i) Thyroid carcinoma, PTC, FTC or HCC confirmed by bioptic analysis of the metastatic lesions or thyroid nodule; ii) clinical hyperthyroidism; iii) hyperthyroidism that persists or develops following total thyroidectomy; iv) increased ^99m^Tc, and/or ^131^I or ^123^I uptake in the metastatic lesion as determined by scintigraphy. Studies involving cases of persistent euthyroidism following total thyroidectomy were also excluded, as this may indicate functioning but not hyperfunctioning thyroid carcinoma.

### Study selection

Since the incidence of hyperfunctioning thyroid carcinoma is very low, the number of cases found on PubMed was small, and the majority of the cases had incomplete data. Of the 763 articles retrieved from PubMed using our search strategy, 397 were duplicated and 324 did not meet the inclusion criteria. Finally, the remaining 42 articles were included in the present study. A detailed flowchart of the study selection process is presented in [Fig. 1](#f1-mco-0-0-1927){ref-type="fig"}.

Results
=======

### Primary hyperfunctioning thyroid carcinoma

The literature search identified 43 cases of primary hyperfunctioning thyroid carcinoma between 1998 and 2017 ([Table I](#tI-mco-0-0-1927){ref-type="table"}) that fulfilled the inclusion criteria ([@b3-mco-0-0-1927],[@b5-mco-0-0-1927]--[@b28-mco-0-0-1927]); the full-text versions of the majority of articles published before 1998 were unavailable. The mean age of patients was 50.1±19.0 years (range, 11--79 years) and the female:male ratio was 2.31 (30:13). All patients presented with clinical hyperthyroidism. Biochemical thyrotoxicosis was confirmed in all patients, apart from 11 cases, 5 of which presented with low TSH and normal T3 and T4 levels, and 6 cases with incomplete information. Thyroid scintigraphy analysis (^99m^Tc and/or ^131^I or ^123^I) was performed in all but 2 patients, and indicated the presence of hot or warm nodules with suppressed uptake in the remainder of the thyroid gland as AFTN. All 43 cases presented with at least one of the following characteristics, indicating that the hyperfunctioning nodule was in fact the thyroid carcinoma: i) Pathological tumor size identical to the size of the nodule as determined by preoperative thyroid scintigraphy analysis; or ii) the thyroid tissue adjacent to the carcinoma was atrophic or normal. The majority of the cases presented with a single hyperfunctioning thyroid carcinoma, apart from 2 cases; patient 23 presented with two hyperfunctioning FTCs, and patient 31 presented with 4 hyperfunctioning PTCs. The mean tumor size was 4.25±2.12 cm. A total of 4.7% of the tumors were ≤1.0 cm in size, 11.6% were \>1 to ≤2.0 cm, 39.5% were \>2 to ≤4.0 cm and 44.2% were \>4.0 cm. Details on the preoperative ultrasound parameters were mostly unavailable; however, based on the available information, there were no characteristic findings indicative of thyroid carcinoma ([Table I](#tI-mco-0-0-1927){ref-type="table"}). The results of fine-needle aspiration (FNA) of the thyroid performed on 15 patients identified differentiated thyroid carcinoma (DTC) or suspected DTC in 10 cases, no diagnosis by cytology in 4 cases, and no malignant characteristics in 1 case. In terms of histological subtype, 20 cases (46.5%) were FTC, 21 cases were PTC \[including 7 follicular variant PTC (FVPTC)\] and 2 cases were HCC.

Of the 15 patients pretreated with anti-thyroid drugs, the results indicated disease control to euthyroid in 8 patients, unknown outcome for 4 patients, no disease control in 2 patients and drug intolerance in 1 patient. Thyroid surgery was performed in all patients. In all patients with available information on disease outcome (n=9), thyrotoxicosis was well-controlled by surgery. Radioactive iodine (RAI) treatment was performed preoperatively in 3 patients who had been initially diagnosed with benign AFTN, and postoperatively in 20 patients. As long-term follow-up data were absent for the majority of the patients, and as patients were treated with RAI within a short time period following surgery, it was difficult to evaluate the effect of RAI alone on those patients. However, the available data indicated that only few (14 cases in 43 cases) suffered recurrence of thyrotoxicosis or carcinoma within a short follow-up period \[44.5 months (6--208 months)\] following thyroid surgery and RAI.

### Metastatic hyperfunctioning thyroid carcinoma

Following a literature search, a total of 28 cases of metastatic hyperfunctioning thyroid cancer were identified ([Table II](#tII-mco-0-0-1927){ref-type="table"}) ([@b3-mco-0-0-1927],[@b4-mco-0-0-1927],[@b29-mco-0-0-1927]--[@b44-mco-0-0-1927]) according to the aforementioned inclusion criteria. All patients had either clinical thyrotoxicosis with biochemical data indicating hyperthyroidism, or been diagnosed as thyrotoxicosis. In addition, all cases (apart from case 56) had a high ^99m^Tc, and/or ^131^I or ^123^I uptake in distant lesions, as demonstrated by whole-body scanning. All patients presented with multiple or large metastases to the bone, lungs, liver or mediastinum. The largest metastatic lesion was observed in the liver of patient 62 (17.0 cm). The mean patient age was 61.2±10.8 years, and the female:male ratio was 1.8 (18:10). Histopathological examination revealed that 20 cases were FTC, 5 cases were PTC (including 1 FVPTC), 1 case was insular TC, and 1 case was an unknown type of DTC. A total of 14 patients with metastatic hyperfunctioning thyroid carcinoma had undergone thyroidectomy, while the remaining 14 patients had no history of thyroidectomy. Thyroid scans were performed in 13 of the 14 cases with no thyroidectomy history, and the results of 6 cases indicated none to normal uptake, cold regions in the thyroid gland and the presence or absence of cold nodules. The remaining 7 cases were diagnosed with AFTN. Thyroid FNAs were performed in 5 cases with no history of thyroidectomy: DTC (1 PTC and 1 FTC) was diagnosed in 2 cases, follicular cells were identified in another 2 cases, and no malignant cells were detected in the remaining case. Biopsies of the metastatic lesions were performed in 3 cases, and the results indicated metastatic DTC. Therefore, of the 14 patients without thyroidectomy, 4 were diagnosed with metastatic hyperfunctioning thyroid cancer, 2 as suspicious and 8 as uncertain.

The results demonstrated that, of the 13 patients who underwent pretreatment with anti-thyroid medication, 6 experienced difficulties or were unable to control thyrotoxicosis, while only 3 patients became euthyroid. The outcome of thyrotoxicosis in the remaining 4 patients was uncertain. Total or subtotal thyroidectomy was performed in 12 of 14 cases without a history of thyroidectomy. One patient succumbed to thyroid crisis at 12 days post-surgery. Following surgery, thyrotoxicosis persisted in 8 patients, while a transient improvement was observed in 3 patients. All patients underwent multi-dose RAI, apart from 2 patients (patient 56 succumbed to the disease and the outcome of patient 64 is unknown). Following RAI, the majority of the patients exhibited a significant improvement in hyperthyroidism and good cancer control; however, thyrotoxicosis in patient 44 persisted for up to 6 months. Patients 55 and 58 experienced no recurrence of thyrotoxicosis or cancer during a follow-up period of 3 or 9 years, respectively following RAI treatment. Of particular note, patient 65 developed RAI resistance 4 years after the first dose of RAI. This patient\'s thyrotoxicosis was caused by pelvic metastasis, which was cleared following surgical removal of the pelvic mass.

Discussion
==========

Thyroid carcinoma coexisting with hyperthyroidism is rare and is more commonly encountered among younger, female patients ([@b5-mco-0-0-1927]). Diagnosis relies on clinical and histopathological correlation. On histopathological examination, the lack of hyperplastic thyroid tissue often suggests a hyperfunctioning thyroid cancer ([@b28-mco-0-0-1927]).

The results of the present study have several implications, as discussed below. First, the prevalence of different histological subtypes of hyperfunctioning thyroid carcinoma was investigated in the present study. The results indicated that 46.5% of primary hyperfunctioning thyroid carcinomas and 71.4% (20/28) of metastatic hyperfunctioning thyroid carcinomas were of the FTC subtype. Mirfakhraee *et al* ([@b5-mco-0-0-1927]) reported that 36.4% (28/77) of solitary hyperfunctioning thyroid nodules harboring a thyroid carcinoma, in which the majority are primary hyperfunctioning thyroid carcinomas, were of the FTC subtype. Qiu *et al* ([@b4-mco-0-0-1927]) reported that the prevalence of FTC in functioning metastatic thyroid carcinoma was 60.5% (23/38), of which 5 cases were hyperfunctioning. By comparison, the Surveillance, Epidemiology and End Results (SEER) cancer registry program (1974--2013) ([@b45-mco-0-0-1927]), which records all histological thyroid cancer cases as a single group, indicates that the prevalence of FTC is 10.8% and that of PTC is 83.6%. Therefore, there appears to be a higher prevalence of FTC among patients with hyperfunctioning thyroid carcinoma, and a particularly high prevalence among patients with metastatic disease. This suggests that hyperfunctioning thyroid carcinoma may be more likely to occur in either primary or metastatic FTC when compared with PTC. The reason for this is unknown. The results presented by Qiu *et al* ([@b4-mco-0-0-1927]) indicate that the prognosis of patients with metastatic hyperfunctioning FTC is worse compared with that for patients with PTC.

Tumor size is an additional important factor to consider for hyperfunctioning thyroid carcinoma. In the present study, the mean tumor size of primary hyperfunctioning thyroid carcinoma was observed to be 4.25±2.12 cm. These results are consistent with those presented by Mirfakhraee *et al* ([@b5-mco-0-0-1927]), who reported a mean tumor size of 4.13±1.68 cm in malignant hot nodules (the majority of which were hyperfunctioning thyroid carcinomas). By comparison, the SEER cancer registry program (1974--2013) ([@b45-mco-0-0-1927]) reports that 28.6% of thyroid carcinomas are ≤1.0 cm in size, 26.0% are \>1.0 to ≤2.0 cm, 23.0% are \>2.0 to ≤4.0 cm, 9.6% are \>4.0 cm and 13.0% are unknown. Pazaitou-Panayiotou *et al* ([@b2-mco-0-0-1927]) conducted a well-organized review, which demonstrated that the majority of non-functioning thyroid carcinomas that coexist with Graves\' disease, toxic nodule goiter or hyperfunctioning adenoma, are microcarcinomas (35.0--88.0%). In addition, similar characteristics were observed in these metastatic hyperfunctioning thyroid carcinoma patients. It is considered that large primary or metastatic tumors may synthesize excessive thyroid hormones more readily, which may cause hyperthyroidism. Somatic mutations in TSH receptor genes may explain the hyperthyroidism caused by thyroid cancer. These mutations activate the intracellular cAMP cascade, induce hormone production and, ultimately, lead to hyperthyroidism ([@b28-mco-0-0-1927],[@b46-mco-0-0-1927]). Pringle *et al* ([@b47-mco-0-0-1927]) observed that thyroid-specific knockout of *PrkarIa* leads to hyperthyroidism and thyroid cancer in mice. Moreover, they suggested that another genetic mutation may be implicated in metastasis, apart from *PrkarIa* mutation in the thyroid ([@b47-mco-0-0-1927]). As DTC cells have similar functions to normal thyroid follicular cells, such as TSH-dependence, absorption of iodine and secretion of thyroglobulin, DTC cells may also secrete thyroxine. When autoregulation mechanisms are impeded, such as in Graves\' disease, large DTCs may secrete excessive amounts of thyroxine resulting in hyperthyroidism. These results also indicate that debulking surgery may play a key role in the treatment of this rare disease.

As regards the diagnosis of hyperfunctioning thyroid carcinoma, it is difficult to distinguish malignant from benign AFTN, as they share common characteristics, such clinical thyrotoxicosis with hot nodules on thyroid scintigraphy. However, the following factors may help determine whether thyrotoxicosis is the result of primary hyperfunctioning thyroid carcinoma: i) No improvement in thyrotoxicosis following RAI treatment (patient 30 in the present systematic review) ([@b16-mco-0-0-1927]); ii) ultrasound results indicating the presence of hypoechoic solid nodules with microcalcifications (patients 23 and 37 in the present systematic review) ([@b10-mco-0-0-1927],[@b23-mco-0-0-1927]); and iii) tumor growth over a short time period (patient 32 and 43 in the present systematic review) ([@b18-mco-0-0-1927],[@b28-mco-0-0-1927]). Additional risk factors for malignancy were also reported, such as age (\<20 or \>60 years), male sex, a family history of DTC, a previous history of head or neck irradiation, tumor fixation to adjacent structures and symptoms of tumor invasion ([@b3-mco-0-0-1927],[@b5-mco-0-0-1927]). Most importantly, AFTN should not be considered to rule out the possibility of malignant thyroid tumor. The applicability of thyroid FNA in differentiating malignant from benign AFTN is limited. This is because \~50% of primary hyperfunctioning thyroid carcinomas are FTCs, which are difficult to distinguish from follicular adenoma by FNA. However, if follicular neoplasms in the thyroid nodule are detected by FNA, combined with high uptake in distant lesions on whole-body scan images and thyrotoxicosis, a diagnosis of metastatic hyperfunctioning thyroid carcinoma, FTC or FVPTC should be considered. Of the 5 metastatic hyperfunctioning thyroid carcinoma patients who underwent FNA, 2 cases were DTC (1 PTC and 1 FTC) and 2 cases were follicular neoplasms; therefore, these 4 patients were diagnosed with metastatic hyperfunctioning thyroid carcinoma. FNA may therefore facilitate the diagnosis of hyperfunctioning metastatic thyroid carcinoma. In 13 of 14 patients with no history of thyroidectomy who underwent thyroid scans, 6 cases demonstrated no increased uptake in the thyroid gland. For these patients, and for patients who develop thyrotoxicosis following total/subtotal thyroidectomy, a diagnosis of metastatic hyperfunctioning thyroid carcinoma should be considered and a whole-body scan should be performed with other additional imaging methods in order to identify metastatic lesions. Core needle aspiration and pathological analysis by H&E staining may also facilitate the diagnosis of primary or metastatic thyroid carcinoma. Hyperfunctioning thyroid carcinoma will require diagnosis by FNA or core needle aspiration and whole-body scanning, as well as confirmation of clinical thyrotoxicosis.

Drug management is considered more suitable for primary hyperthyroidism with Graves\' disease. However, based on our clinical experience, favorable clinical benefits may be achieved with early surgery in cases with secondary hyperthyroidism caused by nodular goiter or thyroid adenoma. Furthermore, surgery can effectively cure patients with hyperthyroidism with non-functioning thyroid carcinomas. For the treatment of hyperfunctioning thyroid carcinoma, the primary aim is to control hyperthyroidism, as well as the cancer itself. Therefore, surgery, particularly total thyroidectomy, is the first-line treatment option for patients with primary hyperfunctioning thyroid carcinoma, as it does not only confirm the diagnosis following pathological examination, but also resolves thyrotoxicosis and cures the cancer. Of the 43 patients in the present study, all except 4 patients diagnosed preoperatively by FNA, were diagnosed with thyroid carcinoma following thyroid surgery. In addition, all 43 patients developed euthyroidism/hypothyroidism within a short time-period following surgery. However, total thyroidectomy may not be the optimal first-line treatment option for patients with hyperfunctioning metastatic lesions with non-functioning primary thyroid carcinoma (as indicated by no increased uptake on thyroid scintigraphy). This is because a total thyroidectomy is unable to control thyrotoxicosis and may even lead to deterioration, as the majority of hormones are produced by metastatic lesions. Of the 5 cases who had undergone total or subtotal thyroidectomy, postoperative thyrotoxicosis persisted in 3 patients, transient improvements were observed in 1 patient, and the remaining patient succumbed to thyroid crisis 12 days after surgery. In addition, the significance of total thyroidectomy in terms of ^131^I therapy was markedly lower in patients with low thyroid bed ^131^I uptake and intense ^131^I uptake in distant metastatic lesions. However, for patients with functional primary and metastatic tumors, total thyroidectomy may be the optimal primary treatment option, as it eliminates the hot primary thyroid carcinoma, which produces a certain amount of thyroid hormones, removes the thyroid gland and reduces the ^131^I dose required to treat the metastatic lesions. In addition, total thyroidectomy and subsequent pathological diagnosis may be particularly useful for patients who have not undergone a preoperative FNA.

RAI is necessary for treating hyperfunctioning metastatic lesions in patients with thyroid carcinoma ([@b4-mco-0-0-1927]); it is a first-line treatment option for patients with a history of thyroidectomy or for those with no increased uptake in the thyroid gland. To avoid a possible thyroid storm, pretreatment with antithyroid medication is required. Fractionated RAI (as for patient 66 in the present systematic review) ([@b44-mco-0-0-1927]), or minimal invasive local ablation may also be considered (as for patient 62 in the present systematic review) ([@b40-mco-0-0-1927]). If the metastatic lesion is resistant to RAI and the functioning lesion resectable, surgery may be considered as a treatment option. This was demonstrated in patient 65 ([@b43-mco-0-0-1927]), whose thyrotoxicosis disappeared following surgical removal of the functioning pelvic mass. However, it is difficult to evaluate the efficiency of RAI following surgery in patients with primary functioning thyroid carcinoma without metastasis. As the majority of primary hyperfunctioning thyroid tumors were large, and metastasis was reported during follow-up post-surgery, RAI was considered as a treatment option following surgery in patients with primary hyperfunctioning thyroid carcinoma ([@b12-mco-0-0-1927],[@b19-mco-0-0-1927]).

In conclusion, the results of the present study indicated that the size of hyperfunctioning thyroid tumors is markedly larger, and primary or metastatic FTC is more commonly hyperfunctioning compared with PTC. FNA or core needle aspiration together with whole-body scanning may play a key role in the diagnosis of clinical thyrotoxicosis. In addition, surgery and RAI are the preferred treatments for primary and metastatic hyperfunctioning thyroid carcinoma, respectively. However, there were certain limitations to the present study: We evaluated studies using the Newcastle-Ottawa Scale and the scores of the studies ranged 2--4. Considering that the number of hyperfunctioning thyroid carcinomas is small and most studies are published as case reports, a risk of bias may exist and the results must be interpreted with caution.
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###### 

Reported cases of primary hyperfunctioning thyroid carcinoma.

  A, Study ID, patient characteristics and findings on examination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------ ------------------ ------------------------------------------------------------ ----------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------- ----------------------- ----------------------- -------- -------- ------------------- ----- -------------------------------------------------------- --------------------------------- -------------------------------------- -----------------------
  1                                                                  Appetecchia        1998                                                         23                                  F                                                   3.5→ 4.0 cm                                         AFTN                                      Chemical                11.55↑                  25.52↑   0.11↓    3.5/4               4     Inhomogeneous nodule                                                                       Gross PTC, 4 PTC, 3 microfoci PTC      ([@b6-mco-0-0-1927])
  2                                                                  Mircescu           2000                                                         11                                  F                                                                                                       Yes, hyperfunctioning nodule              Chemical                                        75↑      0.03↓    4.5                 4     Enlarged with numerous cystic lesions                                                      PTC 4.0 cm, cystic                     ([@b7-mco-0-0-1927])
  3                                                                  Bourasseau         2000                                                         47                                  M                                                                                                       Yes, hot, solitary                        Chemical                ↑                       N        0.05↓    3.5                 3.5   Solitary                                                 Suspicious                        PTC                                    ([@b8-mco-0-0-1927])
  4                                                                  Bourasseau         2000                                                         36                                  M                                                                                                       Yes, hot, solitary                        No                      N                       N        0.025↓   2.5                 2.5   Solitary                                                 No diagnostic                     FTC                                    ([@b8-mco-0-0-1927])
  5                                                                  Bourasseau         2000                                                         56                                  M                                                                                                       Yes, hot, solitary                        Chemical                                        ↑        0.03↓    5.5                 5.5   Solitary                                                 No                                FTC                                    ([@b8-mco-0-0-1927])
  6                                                                  Bourasseau         2000                                                         39                                  F                                                                                                       Yes, warm                                 Chemical                ↑                       ↑        0.004↓   1                   1     Multinodular                                             Suspicious                        PTC                                    ([@b8-mco-0-0-1927])
  7                                                                  Bourasseau         2000                                                         33                                  F                                                                                                       Yes, hot                                  No                      N                                0.005↓   3                   3     Multinodular                                             Not diagnostic                    PTC                                    ([@b8-mco-0-0-1927])
  8                                                                  Camacho            2000                                                         49                                  F                                                                                                       Yes, Hot, AFTN                            Chemical                                        15.7↑    0.04↓    3.5                 3.5                                                            No                                FTC with hemorrhagic central portion   ([@b9-mco-0-0-1927])
  9                                                                  Als                2002                                                         54                                  M                                                                                                       Hot, AFTN                                 Uncertain                                                         8.5                 8.5                                                            No                                FTC                                    ([@b3-mco-0-0-1927])
  10                                                                 Als                2002                                                         62                                  F                                                                                                       Uncertain                                 Uncertain                                                                                                                                            No                                PTC                                    ([@b3-mco-0-0-1927])
  11                                                                 Als                2002                                                         50                                  M                                                                                                       Hot, AFTN                                 Uncertain                                                         10                  10                                                             No                                FTC                                    ([@b3-mco-0-0-1927])
  12                                                                 Als                2002                                                         62                                  M                                                                                                       Hot, AFTN                                 Chemical                ↑                       N        ↓        8                   8                                                              No                                FTC                                    ([@b3-mco-0-0-1927])
  13                                                                 Als                2002                                                         71                                  F                                                                                                       Hot, AFTN                                 Chemical                ↑                       ↑        ↓        4                   4                                                              No                                FTC                                    ([@b3-mco-0-0-1927])
  14                                                                 Als                2002                                                         69                                  F                                                                                                       Hot, AFTN                                 Chemical                ↑                       N        ↓        6                   6                                                              No                                FTC                                    ([@b3-mco-0-0-1927])
  15                                                                 Als                2002                                                         55                                  F                                                                                                       Hot, AFTN                                 Uncertain                                                ↓        5.5                 5.5                                                            No                                FTC                                    ([@b3-mco-0-0-1927])
  16                                                                 Als                2002                                                         79                                  F                                                                                                       Hot, AFTN (suppression)                   Chemical                ↑                       ↑        ↓                                                                                           No                                FTC                                    ([@b3-mco-0-0-1927])
  17                                                                 Als                2002                                                         65                                  M                                                                                                       Hot, AFTN                                 Chemical                ↑                       N        ↓        6.5                 6.5                                                            No                                FTC                                    ([@b3-mco-0-0-1927])
  18                                                                 Als                2002                                                         56                                  M                                                                                                       Hot, AFTN                                 Chemical                ↑                       N                                                                                                    No                                FVPTC                                  ([@b3-mco-0-0-1927])
  19                                                                 Als                2002                                                         75                                  M                                                                                                       Hot, AFTN                                 Chemical                ↑                       N        ↓        5.5                 5.5                                                            No                                FTC                                    ([@b3-mco-0-0-1927])
  20                                                                 Als                2002                                                         77                                  F                                                                                                       Hot, AFTN                                 Chemical                ↑                       N        ↓        4                   4                                                              No                                PTC                                    ([@b3-mco-0-0-1927])
  21                                                                 Als                2002                                                         71                                  F                                                                                                       Hot, AFTN                                 Chemical                ↑                                ↓        6                   6                                                              No                                FTC                                    ([@b3-mco-0-0-1927])
  22                                                                 Als                2002                                                         74                                  F                                                                                                       Hot, AFTN                                 Chemical                ↑                       ↑        ↓        7                   7                                                              No                                FTC                                    ([@b3-mco-0-0-1927])
  23                                                                 Fuhrer             2003                                                         59                                  M                                                                                                       Hot, AFTN right, WBS: no uptake in lung   No                      N                       N        0.01↓    3.5                 3.5   One solid with calcification, one solid                  Lung FNA: FTC                     FTC ×2                                 ([@b10-mco-0-0-1927])
  24                                                                 Wong               2003                                                         67                                  F                                                                                                       Yes, hot, AFTN                            Chemical                                        ↑        ↓        2.5                 3                                                              No feature of carcinoma           Hürthle cell carcinoma                 ([@b11-mco-0-0-1927])
  25                                                                 Gozu               2004                                                                                             F                                                                                                       Yes, hot 5.0 cm, 2.0 cm hypoactive        Chemical                9.11↑                   1.89↑    0.005↓   5                   5                                                              No                                PTC (intracystic)                      ([@b12-mco-0-0-1927])
  26                                                                 Majima             2005                                                         59                                  F                                                                                                       AFTN                                      Chemical                4.4↑                    2.7↑     0.01↓    1.5                 1.5   Hypoechoic with cystic degeneration, calcification       PTC                               PTC                                    ([@b13-mco-0-0-1927])
  27                                                                 Bitterman          2006                                                         57                                  F                                                                                                       Hot in right, cold in left                Possibly                ?                       ?        ?        6                   6     Multinodular                                             Not diagnostic                    FTC                                    ([@b14-mco-0-0-1927])
  28                                                                 Bitterman          2006                                                         59                                  F                                                                                                       Hot, 5 cm AFTN                            Possibly                ?                       ?        ?        5                   5     Solitary nodule                                          No                                FTC                                    ([@b14-mco-0-0-1927])
  29                                                                 Niepomniszcze      2006                                                         64                                  F                                                                                                       Yes, AFTN                                 Chemical                                                 0.02↓    6                   6                                                              no                                FTC                                    ([@b15-mco-0-0-1927])
  30                                                                 Uludag             2008                                                         36                                  M                                                   1.4→ 1.8 cm (11 months)                             AFTN                                      No                      N                       N        0.05↓    1.4                 1.5   Hypoechoic nodule                                        PTC                               PTC                                    ([@b16-mco-0-0-1927])
  31                                                                 Nishida            2008                                                         62                                  F                                                                                                       4 hot AFTN in both lobes                  Chemical                5.2↑                    2.39↑    0.007↓   2.0, 1.5, 0.6,1.5   2.0   Multinodular                                             PTC                               PTC ×4                                 ([@b17-mco-0-0-1927])
  32                                                                 Bommired-dipalli   2010                                                         63                                  M                                                   Enlarging (5 months)                                Yes, AFTN right                           Chemical                N                       2.1↑     0.01↓    4                   4     Solid mass                                               FVPTC?                            FVPTC, LN, FVPTC                       ([@b18-mco-0-0-1927])
  33                                                                 Azevedo            2010                                                         47                                  F                                                   Enlarging (2 years)                                 Yes, high iodine uptake AFTN              Chemical                                        2.75↑    0.05↓    2.6                 3     Solid nodule                                             PTC suggestive                    FVPTC                                  ([@b19-mco-0-0-1927])
  34                                                                 Giovanella         2010                                                         68                                  F                                                                                                       AFTN, no cold area in nodule              Chemical                7.6↑                    N        0.006↓   5.3                 5.3   Hypoechoic nodule                                        No                                FTC                                    ([@b20-mco-0-0-1927])
  35                                                                 Tfayli             2010                                                         11                                  F                                                                                                       Yes, predominant AFTN                     Chemical                                        1.14     ↓        3.5                 3     Non-homogenous nodule                                    Not, diagnostic TC not excluded   PTC                                    ([@b21-mco-0-0-1927])
  36                                                                 Karanchi           2012                                                         43                                  F                                                                                                       AFTN                                      Chemical                12.7↑                   3.1↑     0.01↓    6.5                       Solid nodule                                             No                                Hürthle cell carcinoma                 ([@b22-mco-0-0-1927])
  37                                                                 Nair               2012                                                         38                                  M                                                                                                       Hot, AFTN right lobe whole                Chemical                6.12↑                   2.9↑     0.003↓   3.8                 3     Hypoechoic with scattered microcalcification             NO                                PTC with multifocal microPTC           ([@b23-mco-0-0-1927])
  38                                                                 Ruggeri            2013                                                         15                                  F                                                   2.5→ 3.5 cm (6 months)                              Yes, AFTN                                 Chemical                5.0↑                    20.15↑   0.001↓   3.5                 3.5   Isoechoic, peripheral halo, blood flow, regular margin   No                                FVPTC                                  ([@b24-mco-0-0-1927])
  39                                                                 Mirfakhraee        2013                                                         29                                  F                                                   2.4→ 2.7 cm (2 years)                               Yes, AFTN                                 No                      N                       N        0.005↓   2.7                 2.5   Solid, isoechoic, internal Hypervascularity              No                                FTC                                    ([@b5-mco-0-0-1927])
  40                                                                 Gabalec            2014                                                         15                                  F                                                                                                       Hot, AFTN                                 Chemical                                        30.4↑    0.01↓    4.5                 4     Heterogenous, well-demarcated nodule                     Follicular neoplasia?             FVPTC                                  ([@b25-mco-0-0-1927])
  41                                                                 Kuan               2014                                                         60                                  F                                                   No mention                                          Hot, AFTN right lobe whole                Chemical                7.71↑                   7.75↓    0.005↓   8                   8     Hypoechoic, avascular, nodule                            Follicular neoplasia, FTC?        FVPTC                                  ([@b26-mco-0-0-1927])
  42                                                                 Rees               2015                                                         16                                  F                                                                                                       Yes, 2.6 cm uptake                        Chemical                14.3↑                   39.4↑    0.03↓    4                   4     Hyperechoic, hypervascular nodule                        DTC?                              FVPTC                                  ([@b27-mco-0-0-1927])
  43                                                                 Kadia              2016                                                         37                                  F                                                   Enlarging (3 months)                                --                                        Chemical                                        23.3↑    0.13↓    3.6                 3     Isoechoic, well-defined homogeneous solid nodule         NO                                PTC encapsulated variant               ([@b28-mco-0-0-1927])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **B, Treatment and outcome**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **No.**                                                            **First author**   **Treatment**                                                **Pretreatment effect**             **Surgery outcome**                                 **RAI effect and prognosis**                        **Metastatic**                            **(Refs.)**                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  1                                                                  Appetecchia        Thyroidectomy + bilateral neck dissection + RAI              Triamazole to euthyroid             Hypothyroid, but anterior cervical tumor residual   No thyrotoxicosis or recurrence                                                                                       ([@b6-mco-0-0-1927])                                                                                                                                                                                  
  2                                                                  Mircescu           Right loboisthmectomy/total (2 months) + RAI                 Methimazole + blocker               No mention                                          8 months, no residual uptake                                                                                          ([@b7-mco-0-0-1927])                                                                                                                                                                                  
  3                                                                  Bourasseau         Thyroidectomy                                                No mention                          No mention                                          No                                                                                                                    ([@b8-mco-0-0-1927])                                                                                                                                                                                  
  4                                                                  Bourasseau         Thyroidectomy                                                No mention                          No mention                                          No                                                                                                                    ([@b8-mco-0-0-1927])                                                                                                                                                                                  
  5                                                                  Bourasseau         Thyroidectomy                                                No mention                          No mention                                          No                                                                                                                    ([@b8-mco-0-0-1927])                                                                                                                                                                                  
  6                                                                  Bourasseau         Thyroidectomy                                                No mention                          No mention                                          No                                                                                                                    ([@b8-mco-0-0-1927])                                                                                                                                                                                  
  7                                                                  Bourasseau         Thyroidectomy                                                No mention                          No mention                                          No                                                                                                                    ([@b8-mco-0-0-1927])                                                                                                                                                                                  
  8                                                                  Camacho            Thyroidectomy + RAI                                          No mention                          No mention                                          3 years, no thyrotoxicosis or recurrence                                                                              ([@b9-mco-0-0-1927])                                                                                                                                                                                  
  9                                                                  Als                Surgery + RAI                                                Uncertain                           Uncertain                                           117 months                                          Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  10                                                                 Als                Surgery + RAI + PR                                           Uncertain                           Uncertain                                           82 months                                           Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  11                                                                 Als                Surgery + RAI + PR                                           carbimazole                         Uncertain                                           18 months                                           Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  12                                                                 Als                Surgery + RAI                                                Uncertain                           Uncertain                                           190 months                                          Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  13                                                                 Als                RAI + surgery + RAI                                          Uncertain                           Uncertain                                           68 months                                           Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  14                                                                 Als                Surgery + RAI + PR                                           Uncertain                           Uncertain                                           28 months                                           Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  15                                                                 Als                Surgery + RAI + PR                                           Uncertain                           Uncertain                                           93 months                                           Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  16                                                                 Als                RAI + surgery + RAI                                          Uncertain                           Uncertain                                           46 months                                           Liver and sacrum                          ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  17                                                                 Als                Surgery + RAI + PR                                           Uncertain                           Uncertain                                           107 months                                          Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  18                                                                 Als                Surgery + RAI                                                Uncertain                           Uncertain                                           208 months alive                                    No                                        ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  19                                                                 Als                Surgery + RAI                                                Uncertain                           Uncertain                                           181 months                                          No                                        ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  20                                                                 Als                Surgery + RAI                                                Uncertain                           Uncertain                                           45 months                                           Uncertain                                 ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  21                                                                 Als                Surgery + RAI + PR                                           Uncertain                           Uncertain                                           44 months                                           Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  22                                                                 Als                Surgery + RAI                                                Uncertain                           Uncertain                                           76 months alive                                     Yes                                       ([@b3-mco-0-0-1927])                                                                                                                                                                                                          
  23                                                                 Fuhrer             Total thyroidectomy + RAI - thoracic surgery (8 months)      Euthyroid                           Hypothyroid with RAI                                Hypothyroid, 8 months thyrotoxicosis control good   Yes                                       ([@b10-mco-0-0-1927])                                                                                                                                                                                                         
  24                                                                 Wong               Lobectomy/total thyroidectomy + RAI                          No mention                          No mention                                          No mention                                                                                                            ([@b11-mco-0-0-1927])                                                                                                                                                                                 
  25                                                                 Gozu               Lobectomy/total thyroidectomy + RAI                          Euthyroid                           Hypothyroid (6 weeks)                               1 year, no thyrotoxicosis or recurrence                                                                               ([@b12-mco-0-0-1927])                                                                                                                                                                                 
  26                                                                 Majima             Lobectomy                                                    No mention                          Hypothyroid (3 months)                              No                                                                                                                    ([@b13-mco-0-0-1927])                                                                                                                                                                                 
  27                                                                 Bitterman          Loboisthmectomy + nodule excision/total thyroidectomy        PTU, no clinical improve            Disease-free 1.5 years                              No                                                                                                                    ([@b14-mco-0-0-1927])                                                                                                                                                                                 
  28                                                                 Bitterman          Left lobectomy                                               PTU, intolerance several months     No mention                                          No                                                                                                                    ([@b14-mco-0-0-1927])                                                                                                                                                                                 
  29                                                                 Niepomniszcze      Lobectomy/total thyroidectomy + RAI                          No mention                          No mention                                          6 months, no thyrotoxicosis or recurrence                                                                             ([@b15-mco-0-0-1927])                                                                                                                                                                                 
  30                                                                 Yazici             RAI→total thyroidectomy + CND                                No mention                          No recurrence or residual disease                   Thyrotoxicosis control, but size increase                                                                             ([@b16-mco-0-0-1927])                                                                                                                                                                                 
  31                                                                 Nishida            Total thyroidectomy                                          Thiamazole, 5 months to euthyroid   No recurrence and residual disease (1 year)         No                                                                                                                    ([@b17-mco-0-0-1927])                                                                                                                                                                                 
  32                                                                 Bommireddipalli    Total thyroidectomy + RAI                                    No                                  No mention                                          1 year, TG↑LN +, 1.5 year, LN biopsy +              Yes                                       ([@b18-mco-0-0-1927])                                                                                                                                                                                                         
  33                                                                 Azevedo            Total thyroidectomy + RAI                                    Methimazole 2 months to euthyroid   True hypothyroidism (2 months) then RAI             3 years + 2 years no thyrotoxicosis or recurrence                                                                     ([@b19-mco-0-0-1927])                                                                                                                                                                                 
  34                                                                 Giovanella         Right loboisthmectomy + RAI                                  No                                  Hypothyroid                                         3.4 years, negative                                                                                                   ([@b20-mco-0-0-1927])                                                                                                                                                                                 
  35                                                                 Tfayli             Lobectomy/total thyroidectomy + RAI                          No mention                          No mention                                          1 year, no thyrotoxicosis or recurrence                                                                               ([@b21-mco-0-0-1927])                                                                                                                                                                                 
  36                                                                 Karanchi           Hemithyroidectomy/total thyroidectomy (1 year) + RAI         No control                          Euthyroid (2 weeks)                                 No                                                                                                                    ([@b22-mco-0-0-1927])                                                                                                                                                                                 
  37                                                                 Nair               Total thyroidectomy + CND + LND + RAI (4 weeks + 6 months)   Carbimazole to euthyroid            No mention                                          TG 1 year high, LN metastases                       Yes                                       ([@b23-mco-0-0-1927])                                                                                                                                                                                                         
  38                                                                 Ruggeri            Surgery                                                      Methimazole to euthyroid            No mention                                          No                                                                                                                    ([@b24-mco-0-0-1927])                                                                                                                                                                                 
  39                                                                 Mirfakhraee        Left lobectomy                                               No mention                          Euthyroid (6 months) with no recurrence of cancer   No                                                                                                                    ([@b5-mco-0-0-1927])                                                                                                                                                                                  
  40                                                                 Gabalec            Hemithyroidectomy/total thyroidectomy + CND + RAI            Triamazole                          No mention                                          To hypothyroid state                                                                                                  ([@b25-mco-0-0-1927])                                                                                                                                                                                 
  41                                                                 Kuan               Total thyroidectomy                                          No mention                          No mention                                          No                                                                                                                    ([@b26-mco-0-0-1927])                                                                                                                                                                                 
  42                                                                 Rees               Left lobectomy + RAI                                         Carbimazole to euthyroid            No mention                                          Wel-controlled                                                                                                        ([@b27-mco-0-0-1927])                                                                                                                                                                                 
  43                                                                 Kadia              Left lobectomy                                               methimazole + blocker               Euthyroid (2--4 weeks)                              No                                                                                                                    ([@b28-mco-0-0-1927])                                                                                                                                                                                 

M, male; F, female; AFTN, autonomous functioning thyroid nodule; US, ultrasound; FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; LN, lymph node; RAI, radioactive iodine; PR, preoperative radioactive iodine; CND, central neck dissection; LND, lateral neck dissection; TG, thyroglobulin; WBS, whole-body scanning.

###### 

Reported cases of metastatic hyperfunctioning thyroid carcinoma.

  A, Study ID, patient characteristics and findings on examination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ------------------------------------------------------------------ ------------------ ------------------------------------------------ ---------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------ ----------------------- -------- -------- ---------- ------------------------ --------------------- ---------------- ---------------- -----------------------
  44                                                                 Girelli            1990                                             66                                             F                                               No                                              Normal, uptake cold nodules   High uptake in distant lesions                   Clinical                                                                                                              0.01↓    5,300      Bone                     PTC                   Metastatic       PTC PTC          ([@b29-mco-0-0-1927])
  45                                                                 Mizukami           1994                                             64                                             F                                               No                                              Hot AFTN 4.0                  High uptake in distant lesions                   Clinical                                                                                                              ↓                   Bone                     Microfo-llicular      No               FTC              ([@b30-mco-0-0-1927])
  46                                                                 Russo              1997                                             60                                             F                                               No                                              Hot AFTN two                  High uptake in distant lesions (after surgery)   Clinical                                                                             2.8↑                    N        0.06↓    513        Lung                     No                    No               Insular TC       ([@b31-mco-0-0-1927])
  47                                                                 Salvatori          1993                                             79                                             F                                               No                                              Cold areas                    High uptake in distant lesions                   Clinical                                                                             10.4↑                   3.8↑     0.06↓    382        Lung                     FTC                   No               FTC              ([@b32-mco-0-0-1927])
  48                                                                 Als                2002                                             61                                             M                                               No                                              Hot AFTN                      High uptake in distant lesions                   Clinical                                                                                                                                  Uncertain                No                    No               FTC              ([@b3-mco-0-0-1927])
  49                                                                 Als                2002                                             65                                             F                                               No                                              Hot AFTN                      High uptake in distant lesions                   Clinical                                                                                                                                  Uncertain                No                    No               FTC              ([@b3-mco-0-0-1927])
  50                                                                 Als                2002                                             71                                             F                                               No                                              Hot AFTN                      High uptake in distant lesions                   Clinical                                                                                                     ↑        ↓                   Uncertain                No                    No               FTC              ([@b3-mco-0-0-1927])
  51                                                                 Als                2002                                             62                                             F                                               No                                              Hot AFTN                      High uptake in distant lesions                   Clinical                                                                                                              ↓                   Uncertain                No                    No               FTC              ([@b3-mco-0-0-1927])
  52                                                                 Als                2002                                             63                                             M                                               No                                              Hot AFTN                      High uptake in distant lesions                   Clinical                                                                                                     N        ↓                   Uncertain                No                    No               PTC              ([@b3-mco-0-0-1927])
  53                                                                 Sundaraiya         2009                                             68                                             M                                               No                                              Cold nodule                   High uptake in distant lesions                   Clinical                                                                             42.6↑                   100↑     ↓                   Rib                      No                    Rib FTC          FTC multifocal   ([@b33-mco-0-0-1927])
  54                                                                 Damle              2012                                             65                                             M                                               No                                              --                            High uptake in distant lesions                   Clinical                                                                                                              0.03↓    300        Lung, bone               Follicular neoplasm   No               FTC              ([@b34-mco-0-0-1927])
  55                                                                 Damle              2012                                             62                                             M                                               No                                              No uptake                     High uptake in distant lesions                   Clinical                                                                             ↑                       ↑        ↓        300        Bone                     No                    Metastatic FTC                    ([@b34-mco-0-0-1927])
  56                                                                 Gardner            2014                                             66                                             F                                               No                                              Diffuse reduction             No WBS                                           Clinical                                                                             25.1↑                   37.9↑    0.006↓              Lung, bone               No malignant cells                     FVPTV            ([@b35-mco-0-0-1927])
  57                                                                 Kunawudhi          2016                                             43                                             F                                               No                                              Cold                          High uptake in distant lesions                   Clinical                                                                             32.55↑                  6.34↑    0.026↓              Bone, liver              No                    No               FTC              ([@b36-mco-0-0-1927])
  58                                                                 Abs                1991                                             57                                             F                                               Partial thyroid-ectomy                          Normal                        High uptake in distant lesions                   Clinical                                                                                                              0.6↓     640        Mediasti-num                                                    FTC              ([@b37-mco-0-0-1927])
  59                                                                 Lorberb-oym        1996                                             67                                             F                                               Total thyroid-ectomy                                                          High uptake in distant lesions                   Clinical                                                                             273↑                    15.7↑    0.1↓                Hemipelvis                                                      FTC              ([@b38-mco-0-0-1927])
  60                                                                 Yoshimura          1997                                             61                                             M                                               Total thyroidectomy + RAI + hip replacement                                   High uptake in distant lesions                   Clinical                                                                             46.1↑                   105.3↑   0.05↓    329        Pelvis                                                          FTC              ([@b39-mco-0-0-1927])
  61                                                                 Salvatori          1993                                             69                                             F                                               Partial thyroidectomy                           Low uptake                    High uptake in distant lesions                   Clinical                                                                             3.8↑                    10.4↑    0.06↓    48,680     Lung                                                            DTC              ([@b32-mco-0-0-1927])
  62                                                                 Guglielmi          1999                                             58                                             F                                               Subtotal thyroidectomy                                                        High uptake in distant lesions                   Clinical                                                                             18.4↑                   44.5↑    0.1↓     3,686      Liver, lung                                    Liver FTC        FTC              ([@b40-mco-0-0-1927])
  63                                                                 Basaria            2002                                             74                                             M                                               Total thyroidectomy 8 years                                                   High uptake in distant lesions                   Clinical                                                                             ↑                       ↑        ↓        2,280      Mediastinum and lung                                            PTC              ([@b41-mco-0-0-1927])
  64                                                                 Orsolon            2008                                             66                                             M                                               Total thyroidectomy                                                           High uptake in distant lesions                   Clinical                                                                             4.5↑                    1.6      \<0.1↓   \>10,000   Bone, lung                                                      FTC              ([@b42-mco-0-0-1927])
  65                                                                 Tan                2009                                             39                                             F                                               Total thyroidectomy + hip replacement + RAI                                   High uptake in distant lesions (FDG)             Clinical                                                                             27.9↑                   4.41↑    0.01↓    1,000      Pelvic mass                                                     FTC              ([@b43-mco-0-0-1927])
  66                                                                 Nishihara          2010                                             59                                             F                                               Total thyroidectomy + EBRT                                                    High uptake in distant lesions                   Clinical                                                                             ↑                       ↑        0.01↓    8,000      Multiple bone and lung                                          FTC              ([@b44-mco-0-0-1927])
  67                                                                 Qiu                2015                                             45                                             M                                               Total thyroidectomy                                                           High uptake in distant lesions                   Clinical                                                                             13.42↑                  33.9↑    0.04↓               Bone                                                            FTC              ([@b4-mco-0-0-1927])
  68                                                                 Qiu                2015                                             75                                             M                                               Total thyroidectomy                                                           High uptake in distant lesions                   Clinical                                                                             9.35↑                   27.18↑   0.24↓               Lung                                                            PTC              ([@b4-mco-0-0-1927])
  69                                                                 Qiu                2015                                             43                                             F                                               Total thyroidectomy                                                           High uptake in distant lesions                   Clinical                                                                             7.23↑                   29.14↑   0.22↓               Bone                                                            FTC              ([@b4-mco-0-0-1927])
  70                                                                 Qiu                2015                                             51                                             F                                               Total thyroidectomy                                                           High uptake in distant lesions                   Clinical                                                                             9.51↑                   31.73↑   0.02↓               Bone, lung                                                      FTC              ([@b4-mco-0-0-1927])
  71                                                                 Qiu                2015                                             54                                             F                                               Total thyroidectomy                                                           High uptake in distant lesions                   Clinical                                                                             7.83↑                   32.15↑   0.01↓               Bone                                                            FTC              ([@b4-mco-0-0-1927])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **B, Treatment and outcome**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **No.**                                                            **First author**   **Pretreatment antithyroid drug**                **Treatment**                                  **Surgery outcome**                             **Response to RAI**                             **(Refs.)**                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  44                                                                 Girelli            Thyrotoxicosis to subhyperthyroidism             Total thyroidectomy + RAI                      Persistent                                      Hyperthyroidism persisting 6 months after RAI   ([@b29-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  45                                                                 Mizukami           Unknown                                          RAI                                            --                                              Persistent after 2 RAI                          ([@b30-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  46                                                                 Russo              Unknown                                          Subtotal thyroidectomy/1 year total + RAI 2    Mild hyperthyroidism                            Hypothyroid, TG remains high (2 years)          ([@b31-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  47                                                                 Salvatori          Effect not shown                                 Total thyroidectomy + RAI                      Improved only 1 month                           Hyperthyroidism persisting 4 months after RAI   ([@b32-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  48                                                                 Als                Unknown                                          RAI + surgery + RAI                            Persistent                                      27 months, died                                 ([@b3-mco-0-0-1927])                                                                                                                                                                                                                                                                                      
  49                                                                 Als                Unknown                                          RAI + surgery + RAI                            Persistent                                      39 months, died                                 ([@b3-mco-0-0-1927])                                                                                                                                                                                                                                                                                      
  50                                                                 Als                Unknown                                          Surgery + RAI                                  Persistent                                      229 months, died                                ([@b3-mco-0-0-1927])                                                                                                                                                                                                                                                                                      
  51                                                                 Als                Unknown                                          Surgery + RAI                                  Persistent, possible improvement                10 months, died                                 ([@b3-mco-0-0-1927])                                                                                                                                                                                                                                                                                      
  52                                                                 Als                Unknown                                          Surgery + RAI                                  Persistent                                      71 months, died                                 ([@b3-mco-0-0-1927])                                                                                                                                                                                                                                                                                      
  53                                                                 Sundaraiya         Effect not shown                                 Total thyroidectomy + RAI                      Persistent                                      3 months RAI hypothyroid with tumor control     ([@b33-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  54                                                                 Damle              Thyrotoxicosis difficult to control              Subtotal thyroidectomy + RAI                   Improved only 2 months                            5 years of no recurrence of thyrotoxicosis    ([@b34-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  55                                                                 Damle              Thyrotoxicosis difficult to control              RAI                                            --                                              3 years of no recurrence of thyrotoxicosis      ([@b34-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  56                                                                 Gardner            Thyrotoxicosis difficult to control              Total thyroidectomy + RAI                      Died of thyroid storm 12 days postoperatively   --                                              ([@b35-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  57                                                                 Kunawudhi          Effect not shown                                 Total thyroidectomy + right LND + RAI + EBRT   Persistent                                      2 years, progressive disease                    ([@b36-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  58                                                                 Abs                Thyrotoxicosis difficult to control                Rib biopsy + RAI, good                                                                                                                                                                                                      RAI 9 years, no metastases                                                           ([@b37-mco-0-0-1927])                                                                                                                 
  59                                                                 Lorberboym         Pretreatment to euthyroid +EBRT to hypothyroid   Pretreatment + EBRT + RAI                                                                                                                                                                                                     4 weeks RAI hypothyroid                                                              ([@b38-mco-0-0-1927])                                                                                                                 
  60                                                                 Yoshimura          No mention                                       RAI + pretreatment                                                                                                                                                                                                            Rapid improvement 1.5 years survival                                                 ([@b39-mco-0-0-1927])                                                                                                                 
  61                                                                 Salvatori          Effect not shown                                 RAI                                                                                                                                                                                                                           Hyperthyroidism persisting 6 months after RAI                                        ([@b32-mco-0-0-1927])                                                                                                                 
  62                                                                 Guglielmi          Failure to control thyrotoxicosis                ILP + RAI                                                                                                                                                                                                                     1.5 years good control                                                               ([@b40-mco-0-0-1927])                                                                                                                 
  63                                                                 Basaria            Good control                                     Pretreatment + RAI                                                                                                                                                                                                            3 months hypothyroid                                                                 ([@b41-mco-0-0-1927])                                                                                                                 
  64                                                                 Orsolon            Unknown                                          Unknown                                                                                                                                                                                                                       Unknown                                                                              ([@b42-mco-0-0-1927])                                                                                                                 
  65                                                                 Tan                Worsening                                        Removal of pelvis mass and partial bone        Thyrotoxicosis disappeared                      Resistant to RAI                                ([@b43-mco-0-0-1927])                                                                                                                                                                                                                                                                                     
  66                                                                 Nishihara          Unknown                                          RAI low multiple                                                                                                                                                                                                              10 months after RAI, toxicosis control, but tumor progression, 8 years of survival   ([@b44-mco-0-0-1927])                                                                                                                 
  67                                                                 Qiu                Unknown                                          RAI + palliative resection                                                                                                                                                                                                    Effect not clearly shown                                                                                                                                                                                                   
  68                                                                 Qiu                Unknown                                          RAI                                                                                                                                                                                                                           Effect not clearly shown                                                             ([@b4-mco-0-0-1927])                                                                                                                  
  69                                                                 Qiu                Unknown                                          RAI + palliative resection                                                                                                                                                                                                    Effect not clearly shown                                                             ([@b4-mco-0-0-1927])                                                                                                                  
  70                                                                 Qiu                Unknown                                          RAI + palliative resection                                                                                                                                                                                                    Effect not clearly shown                                                             ([@b4-mco-0-0-1927])                                                                                                                  
  71                                                                 Qiu                Unknown                                          RAI                                                                                                                                                                                                                           Effect not clearly shown                                                             ([@b4-mco-0-0-1927])                                                                                                                  

M, male; F, female; RAI, radioactive iodine; EBRT, external beam radiation therapy; AFTN, autonomous functioning thyroid nodule; FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; TC, thyroid carcinoma; DTC, differentiated thyroid carcinoma; LND, lateral neck dissection; ILP, interstitial laser photocoagulation; TG, thyroglobulin; LN, lymph node.
